checkAd

     105  0 Kommentare Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW 2024

    Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week (DDW) 2024, May 18-21 in Washington, D.C. This includes data on Cologuard, the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus. Further details can be found at ddw.org.

    “At Exact Sciences, we know colorectal cancer screening must be able to find and also help prevent the disease to positively impact patient outcomes, which is how the Cologuard test was designed,” said Paul Limburg, MD, MPH, AGAF, chief medical officer for screening, Exact Sciences. “In addition to effective detection rates for cancers, pre-cancers and low false positive rates, patients need options that are convenient and easy to use. Up to 40% of the screening-eligible population in the U.S. currently needs to be screened for colorectal cancer and our data at DDW can inform strategies to meaningfully address this critical gap.”1

    The following abstracts from Exact Sciences have been accepted for presentation at the annual meeting:

    Session Type: Research Forum
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Session Date & Time: Saturday, May 18, from 12:30 p.m. to 1:30 p.m. EDT
    Presentation Title: Comparison Of Efficient Frontier Strategies For Guideline-endorsed Vs Non-endorsed Colorectal Cancer Screening Tests

    Session Type: Research Forum
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Session Date & Time: Saturday, May 18, from 12:30 p.m. to 1:30 p.m. EDT
    Presentation Title: Comparison Of Efficient Frontier Strategies For Stool-based Colorectal Cancer Screening Tests

    Session Type: Research Forum
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
    Session Date & Time: Saturday, May 18, from 12:30 p.m. to 1:30 p.m. EDT
    Presentation Title: Estimated Average-risk Colorectal Cancer Screening-eligible Population In The U.S.

    Session Type: Research Forum
    Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials

    Seite 1 von 4



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW 2024 Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies and advancements for improving colorectal cancer screening rates and outcomes …

    Schreibe Deinen Kommentar

    Disclaimer